This study validates SOX2 as a promising therapeutic target for HNSCC and confirms the efficacy of αEGFR‐SOX2‐CRISPR‐LNPs (cLNP) as an intratumoral therapy for visible and palpable HNSCC. This evidence concerns the gene SOX2 and head and neck squamous cell carcinoma.